PROMISE (Program Refinements to Optimize Model Impact and Scalability based on Evidence): A cluster-randomized, stepped-wedge trial assessing effectiveness of the revised versus original Ryan White Part A HIV Care Coordination Program for patients with barriers to treatment

enthalten in: bioRxiv.org | 2022

von Irvine, M. | Levin, B. | Robertson, M. | +5

What’s the matter with MICs: The contribution of nutrients and limiting resources to the pharmacodynamics of antibiotics and bacteria

enthalten in: bioRxiv.org | 2022

von Berryhill, B. | Gil-Gil, T. | Manuel, J. | +4

The population and evolutionary dynamics of bacteriophage: Why be temperate revisited

enthalten in: bioRxiv.org | 2022

von Chaudhry, W. | Vega, N. | Govindan, A. | +4

Promises and pitfalls ofin vivoevolution to improve phage therapy

enthalten in: bioRxiv.org | 2022

von Bull, J. | Levin, B. | Molineux, I.

Using Lambda phages as a proxy for pathogen transmission in hospitals

enthalten in: bioRxiv.org | 2022

von Burke, K. | Berryhill, B. | Garcia, R. | +6

What the book of Lambda doesn’t tell us about temperate phages and lysogeny in the real world

enthalten in: bioRxiv.org | 2022

von Berryhill, B. | Garcia, R. | McCall, I. | +3

Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin inStaphylococcus aureus

enthalten in: bioRxiv.org | 2021

von Friberg, C. | Haaber, J. | Vestergaard, M. | +4

Mucoidy, a general mechanism for maintaining lytic phage in populations of bacteria

enthalten in: bioRxiv.org | 2020

von Chaudhry, W. | Lee, E. | Worthy, A. | +4

Immune Loss as a Driver of Coexistence During Host-Phage Coevolution

enthalten in: bioRxiv.org | 2020

von Weissman, J. | Holmes, R. | Barrangou, R. | +4

Antibiotic susceptibility of bacterial colonies: An assay and experiments withStaphylococcus aureus

enthalten in: bioRxiv.org | 2020

von Shao, X. | Kim, J. | Jeong, H. | +1